Ampio Pharmaceuticals (AMPE) 10-Q 4 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Jul. 30, 2021
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-35182
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-0179592
Entity Address, Address Line One	373 Inverness Parkway, Suite 200
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AMPE
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		200,457,957
Entity Central Index Key	0001411906
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 20,549,000	$ 17,346,000
Prepaid expenses and other	2,358,000	1,147,000
Total current assets	22,907,000	18,493,000
Fixed assets, net	3,074,000	3,561,000
Right-of-use asset	728,000	824,000
Total assets	26,709,000	22,878,000
Current liabilities
Accounts payable and accrued expenses	2,937,000	1,550,000
Lease liability-current portion	298,000	284,000
Total current liabilities	3,235,000	1,834,000
Lease liability-long-term	773,000	925,000
Warrant derivative liability	2,340,000	2,607,000
Total liabilities	6,348,000	5,366,000
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $0.0001; 300,000,000 shares authorized; shares issued and outstanding - 200,070,419 as of June 30, 2021 and 193,378,996 as of December 31, 2020	20,000	19,000
Additional paid-in capital	228,091,000	218,020,000
Accumulated deficit	(207,750,000)	(200,527,000)
Total stockholders' equity	20,361,000	17,512,000
Total liabilities and stockholders' equity	$ 26,709,000	$ 22,878,000

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Condensed Balance Sheets
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	200,070,419	193,378,996
Common Stock, shares outstanding	200,070,419	193,378,996

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses
Research and development	$ 2,273,000	$ 1,118,000	$ 4,568,000	$ 5,373,000
General and administrative	1,400,000	1,482,000	2,923,000	3,249,000
Total operating expenses	3,673,000	2,600,000	7,491,000	8,622,000
Other income (expense)
Interest income	1,000	0	2,000	12,000
Paycheck Protection Program loan forgiveness		544,000	0	544,000
Derivative gain (loss)	116,000	(675,000)	267,000	156,000
Total other income (expense)	117,000	(131,000)	269,000	712,000
Net loss	$ (3,556,000)	$ (2,731,000)	$ (7,222,000)	$ (7,910,000)
Net loss per common share: Basic	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.05)
Net loss per common share: Diluted	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.05)
Weighted average number of common shares outstanding: Basic	196,179,371	166,392,893	195,785,398	162,723,309
Weighted average number of common shares outstanding: Diluted	201,448,038	166,392,893	200,985,349	163,906,257

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]At The Market Equity Offering Program	Common Stock [Member]	Additional Paid-in CapitalAt The Market Equity Offering Program	Additional Paid-in Capital	Accumulated DeficitAt The Market Equity Offering Program	Accumulated Deficit	At The Market Equity Offering Program	Total
Beginning Balance at Dec. 31, 2019		$ 16		$ 191,060		$ (184,633)		$ 6,443
Beginning Balance, Shares at Dec. 31, 2019		158,644,757
Issuance of common stock for services		$ 0		80		0		80
Issuance of common stock for services (Shares)		136,236
Stock-based compensation, net of forfeitures		$ 0		213		0		213
Issuance of common stock	$ 0		$ 682		$ 0		$ 682
Issuance of common stock (Shares)	1,241,126
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program		0		(246)		0		(246)
Net loss		0		0		(5,179)		(5,179)
Ending Balance at Mar. 31, 2020		$ 16		191,789		(189,812)		1,993
Ending Balance, Shares at Mar. 31, 2020		160,022,119
Beginning Balance at Dec. 31, 2019		$ 16		191,060		(184,633)		6,443
Beginning Balance, Shares at Dec. 31, 2019		158,644,757
Net loss								(7,910)
Ending Balance at Jun. 30, 2020		$ 17		198,869		(192,543)		6,343
Ending Balance, Shares at Jun. 30, 2020		173,341,950
Beginning Balance at Mar. 31, 2020		$ 16		191,789		(189,812)		1,993
Beginning Balance, Shares at Mar. 31, 2020		160,022,119
Stock-based compensation, net of forfeitures		$ 0		64		0		64
Stock options exercised, net		$ 0		0		0		0
Stock options exercised, net (Shares)		1,314
Warrants exercised, net		$ 0		100		0		100
Warrants exercised, net (Shares)		250,000
Issuance of common stock	$ 1		7,230		0		7,231
Issuance of common stock (Shares)	13,068,517
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program		$ 0		(314)		0		(314)
Net loss		0		0		(2,731)		(2,731)
Ending Balance at Jun. 30, 2020		$ 17		198,869		(192,543)		6,343
Ending Balance, Shares at Jun. 30, 2020		173,341,950
Beginning Balance at Dec. 31, 2020		$ 19		218,020		(200,527)		17,512
Beginning Balance, Shares at Dec. 31, 2020		193,378,996
Issuance of common stock for services		$ 0		80		0		80
Issuance of common stock for services (Shares)		54,052
Stock-based compensation, net of forfeitures		$ 0		166		0		166
Stock options exercised, net		$ 0		33		0		33
Stock options exercised, net (Shares)		129,500
Shares held back in settlement of tax obligation and exercise cost		$ 0		(40)		0		(40)
Shares held back in settlement of tax obligation and exercise cost (Shares)		(28,562)
Warrants exercised, net		$ 0		114		0		114
Warrants exercised, net (Shares)		306,705
Issuance of common stock	$ 0		2,705		0		2,705
Issuance of common stock (Shares)	1,848,437
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program		$ 0		(126)		0		(126)
Net loss		0		0		(3,667)		(3,667)
Ending Balance at Mar. 31, 2021		$ 19		220,952		(204,194)		16,777
Ending Balance, Shares at Mar. 31, 2021		195,689,128
Beginning Balance at Dec. 31, 2020		$ 19		218,020		(200,527)		17,512
Beginning Balance, Shares at Dec. 31, 2020		193,378,996
Net loss								(7,222)
Ending Balance at Jun. 30, 2021		$ 20		228,091		(207,750)		20,361
Ending Balance, Shares at Jun. 30, 2021		200,070,419
Beginning Balance at Mar. 31, 2021		$ 19		220,952		(204,194)		16,777
Beginning Balance, Shares at Mar. 31, 2021		195,689,128
Stock-based compensation, net of forfeitures		$ 0		67		0		67
Stock options exercised, net		$ 0		127		0		127
Stock options exercised, net (Shares)		314,162
Shares held back in settlement of tax obligation and exercise cost		$ 0		0		0		0
Shares held back in settlement of tax obligation and exercise cost (Shares)		(28,802)
Warrants exercised, net		$ 0		0		0		0
Warrants exercised, net (Shares)		29,158
Issuance of common stock	$ 1		$ 7,266		$ 0		$ 7,267
Issuance of common stock (Shares)	4,066,773
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program		$ 0		(321)		0		(321)
Net loss		0		0		(3,556)		(3,556)
Ending Balance at Jun. 30, 2021		$ 20		$ 228,091		$ (207,750)		$ 20,361
Ending Balance, Shares at Jun. 30, 2021		200,070,419

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows used in operating activities
Net loss	$ (7,222)	$ (7,910)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation, net of forfeitures	233	277
Depreciation and amortization	568	591
Paycheck Protection Program loan forgiveness	0	(544)
Issuance of common stock for services	80	80
Derivative gain (loss)	(267)	(156)
Changes in operating assets and liabilities
Increase in prepaid expenses and other	(1,211)	(229)
Increase (decrease) in accounts payable and accrued expenses	1,386	(1,758)
Decrease in lease liability	(42)	(38)
Proceeds received under the Paycheck Protection Program	0	544
Net cash used in operating activities	(6,475)	(9,143)
Cash flows used in investing activities
Purchase of fixed assets	(81)	0
Net cash used in investing activities	(81)	0
Cash flows from financing activities
Proceeds from sale of common stock in connection with "at-the-market" equity offering program	9,972	7,913
Costs related to sale of common stock in connection with the "at-the-market" equity offering program	(447)	(560)
Proceeds from warrant and stock option exercises, net	234	100
Net cash provided by financing activities	9,759	7,453
Net change in cash and cash equivalents	3,203	(1,690)
Cash and cash equivalents at beginning of period	17,346	6,532
Cash and cash equivalents at end of period	20,549	4,842
Non-cash transactions:
Commercial insurance premium financing agreement	$ 1,016	$ 1,347

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
The Company and Summary of Significant Accounting Policies
The Company and Summary of Significant Accounting Policies	Note 1 – The Company and Summary of Significant Accounting Policies Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. Basis of Presentation ​ The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions of the SEC on Quarterly Reports on Form 10-Q and Article 8 of Regulation S-X. Accordingly, such financial statements do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the financial position and of the results of operations and cash flows of the Company for the periods presented. ​ These financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2020 included in the Company’s 2020 Annual Report. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The information as of and for the three and six months ended June 30, 2021 is unaudited. The balance sheet at December 31, 2020 was derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. Impact of Global Pandemic ​ In January 2020, the Secretary of Health and Human Services (“HHS”) declared a public health emergency and the World Health Organization (“WHO”) announced a global health emergency because of the novel Coronavirus Disease 2019 (“COVID-19”). In March 2020, the WHO declared the outbreak of COVID-19, a global pandemic. Since the declaration of the outbreak, COVID-19 has adversely impacted and continues to adversely impact the United States and global economies. In April 2020, and pursuant to the U.S. Food and Drug Administration (“FDA”), independent Safety Monitoring Committee (“SMC”), and Institutional Review Board guidance covering ongoing clinical trials in the presence of the COVID-19 pandemic, the Company and the clinical research organization (“CRO”) paused all ongoing conduct associated with the Phase III clinical trial (the “AP-013 study”) of Ampion for the treatment of Osteoarthritis of the Knee (“OAK”). In March 2021, the Company submitted a detailed proposal to the FDA in response to the FDA’s guidance regarding the status of the AP-013 study. In April 2021, the Company received a response to the proposal from the FDA, which provides guidance and flexibility on how to maintain the Special Protocol Assessment (“SPA”), while allowing the Company to evaluate and consider several paths for moving forward. In May 2021, the FDA issued updated statistical guidance for the industry. At this time, the Company is evaluating its options to analyze the clinical trial data from the AP-013 study. ​ In addition, since June 2020, the Company has commenced several clinical trials to determine the safety and efficacy for new applications of Ampion (i.e., inhaled and intravenous) related to COVID-19 infection. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the Company’s business operations could be significantly impacted and, in addition, the business operations of third parties on which the Company relies, including organizations that conduct clinical trials and key suppliers which provide the raw materials for manufacturing Ampion for the ongoing clinical trials could also be impacted. The full extent of the potential adverse impact on the Company’s business operations and related current and future product development, including, but not limited to, clinical trials, financing activities and the overall impact on the United States and the global economy will depend on future developments related to the pandemic, which cannot be predicted at this time. ​ Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and fully liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the three and six months ended June 30, 2021, and as consistent with prior reporting periods, the Company maintained balances in excess of federally insured limits. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s projected liquidity and resulting going concern position, clinical trial accrual and the projected useful lives and potential impairment of fixed assets. The Company develops these estimates using its judgment based upon the facts and circumstances known at the time. Adoption of Recent Accounting Pronouncements The Company has not adopted any recent accounting pronouncements during the six months ended June 30, 2021. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “ Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2021
Going Concern
Going Concern	Note 2 - Going Concern As of and for the six months ended June 30, 2021, the Company had cash and cash equivalents of $20.5 million and a net loss of $7.2 million, respectively. The net loss is primarily attributable to operating expenses of $7.5 million, partially offset by the non-cash derivative gain of $0.3 million (see Note 9 devote substantially all of their efforts and resources to research and development, as well as clinical trials, and do not yet have commercialized products. These existing and projected on-going factors continue to raise substantial doubt about the Company’s ability to continue as a going concern. In February 2020, the Company entered into a Sales Agreement (“Sales Agreement”) with two agents to implement an “at-the-market” (“ATM”) equity offering program under which the Company, from time to time and at its sole discretion, may issue and sell shares of its authorized common stock. During the six months ended June 30, 2021, the Company sold shares pursuant to the ATM equity offering program, which yielded gross proceeds of approximately $10.0 million, which was offset by offering related costs of $0.4 million (see Note 10 ​ The Company has prepared an updated projection covering the period from July 1, 2021 through August 31, 2022 based on the requirements of ASC 205-40, “ Going Concern ​ The accompanying unaudited interim financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any separate adjustments relating to the recovery of recorded assets or the classification of liabilities, which adjustments may be necessary in the future should the Company be unable to continue as a going concern.

Prepaid Expenses and Other

Prepaid Expenses and Other	6 Months Ended
	Jun. 30, 2021
Prepaid Expenses and Other
Prepaid Expenses and Other	Note 3 – Prepaid Expenses and Other Prepaid expenses and other balances as of June 30, 2021 and December 31, 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ ​ ​ ​ ​ Deposits ​ $ 1,236,000 ​ $ 266,000 Unamortized commercial insurance premiums ​ ​ 981,000 ​ ​ 627,000 Annual maintenance service contracts ​ ​ 63,000 ​ ​ — Receivable ​ ​ 30,000 ​ ​ 185,000 Other ​ ​ 48,000 ​ ​ 69,000 Total prepaid expenses and other ​ $ 2,358,000 ​ $ 1,147,000 ​

Fixed Assets

Fixed Assets	6 Months Ended
	Jun. 30, 2021
Fixed Assets
Fixed Assets	Note 4 – Fixed Assets Fixed assets are recorded based on acquisition cost and, once placed in service, are depreciated utilizing the straight-line method over their estimated economic useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease term. Fixed assets, net of accumulated depreciation and amortization, consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ ​ Useful Lives ​ June 30, ​ December 31, ​ (in Years) 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements 10 ​ $ 1,950,000 ​ $ 2,250,000 Manufacturing facility/clean room 3 - 8 ​ ​ 834,000 ​ ​ 998,000 Lab equipment and office furniture 5 - 8 ​ 290,000 ​ 313,000 Fixed assets, net ​ ​ ​ $ 3,074,000 ​ $ 3,561,000 ​ Depreciation and amortization expense for the respective periods is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization expense ​ $ 274,000 ​ $ 296,000 ​ $ 568,000 ​ $ 591,000 ​ ​

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2021
Accounts Payable and Accrued Expenses
Accounts Payable and Accrued Expenses	Note 5 – Accounts Payable and Accrued Expenses Accounts payable and accrued expenses as of June 30, 2021 and December 31, 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ ​ ​ ​ ​ Accounts payable ​ $ 170,000 ​ $ 186,000 Clinical trials ​ ​ 1,525,000 ​ ​ 558,000 Commercial insurance premium financing ​ 808,000 ​ 386,000 Professional fees ​ 380,000 ​ 267,000 Other ​ ​ 54,000 ​ ​ 153,000 Accounts payable and accrued expenses ​ $ 2,937,000 ​ $ 1,550,000 ​

Paycheck Protection Program

Paycheck Protection Program	6 Months Ended
	Jun. 30, 2021
Paycheck Protection Program
Paycheck Protection Program	Note 6 – Paycheck Protection Program In April 2020, the Company received proceeds of $544,000 via a loan from KeyBank National Association (the “Lender”) that was issued under the Paycheck Protection Program (the “PPP”) established under the Coronavirus Aid, Relief and Economic Security Act. The term of the PPP loan is two years with an annual interest rate of 1.0% and principal and interest payments will be deferred for the first six months of the loan term, which was subsequently updated in accordance with the Paycheck Protection Program Flexibility Act of 2020. ​ In October 2020, the Company submitted its PPP loan forgiveness application, requesting forgiveness of the full principal amount of its PPP loan. In May 2021, the Company received notification from the Lender that the Small Business Administration (the “SBA”) had authorized full forgiveness of the PPP loan. In July 2021, the Company received notification from the Lender that the SBA submitted, and the Lender has received, proceeds representing the full pay-off of the loan balance. As such, the Company’s loan balance is considered to be paid off in full.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total 2021 2022 2023 2024 2025 Thereafter Key clinical research trial obligations ​ $ 3,896,000 ​ $ 2,768,000 ​ $ 1,128,000 ​ $ — ​ $ — ​ $ — ​ $ — Employment agreements ​ ​ 830,000 ​ ​ 351,000 ​ ​ 466,000 ​ ​ 13,000 ​ ​ — ​ ​ — ​ ​ — Commercial insurance premium financing agreement ​ ​ 808,000 ​ ​ 539,000 ​ ​ 269,000 ​ ​ — ​ ​ — ​ ​ — ​ ​ — Statistical analysis and programming consulting services ​ ​ 326,000 ​ ​ 163,000 ​ ​ 163,000 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ $ 5,860,000 ​ $ 3,821,000 ​ $ 2,026,000 ​ $ 13,000 ​ $ — ​ $ — ​ $ — ​ Key Clinical Research Trial Obligations Osteoarthritis of the Knee ​ ​ ​ AP-013 study In December 2020, the Company entered into an initial contract with a CRO in reference to the AP-013 study database totaling $1.4 million. The contractual provisions required a retainer of $315,000, which will be applied to future study expenses as further defined by the contract. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the retainer. In March 2021, the Company submitted a detailed proposal to the FDA in response to the FDA’s guidance regarding the status of the AP-013 study, which was paused as a result of the COVID-19 pandemic. In April 2021, the Company received a response to the proposal from the FDA. In May 2021, the FDA issued updated statistical guidance for the industry. At this time, the Company is evaluating its options to analyze the clinical trial data from the AP-013 study. The Company had an outstanding future contractual commitment of $382,000 (net of deposit) as of June 30, 2021. ​ Inhaled treatment for COVID-19 patients AP-018 study and AP-019 study In March 2021, the Company entered into a contract with a CRO totaling $318,000 in reference to a Phase I study for at-home treatment utilizing inhaled Ampion to treat patients with Post-Acute Sequelae of SARS-CoV-2 infection (“PASC”) commonly referred to as “Long-COVID”, or prolonged respiratory symptoms due to COVID-19 (the “AP-018 study”). The contractual provisions required an initial retainer of $105,000, which will be applied to future study expenses as further defined by the contract. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the retainer. The Company had an outstanding future contractual commitment of $130,000 (net of deposit) as of June 30, 2021. In June 2021, the Company entered into a contract with a CRO totaling $2.5 million in reference to a multicenter Phase II clinical trial, using inhaled Ampion in the treatment of respiratory distress due to COVID-19 (the “AP-019 study”). The contractual provisions required an initial retainer of $300,000, which will be applied to future study expenses as further defined by the contract. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the retainer. The Company had an outstanding future contractual commitment of $2.2 million (net of deposit) as of June 30, 2021. Intravenous (“IV”) treatment for COVID-19 patients AP-017 study In December 2020, the Company entered into a contract with a CRO totaling $1.8 million in reference to a multicenter Phase II clinical trial utilizing IV Ampion in the treatment of patients suffering from complications arising from COVID- 19 (the AP-017 study”). The contractual provisions required a retainer of $345,000, which will be applied to future study expenses as further defined by the contract. The contract currently accounts for 120 patients; however, based on the revised protocol, the number of patients has increased to 200. The Company is in ongoing discussions with the CRO to amend the contractual amount to account for the additional patients expected to be enrolled. In the event of premature termination, the Company will pay for services rendered and expenses incurred through the date of termination. The CRO will refund any unused portion of the retainer. Employment Agreements On December 14, 2019, the Company entered into a three-year employment agreement with Mr. Macaluso, Chief Executive Officer, which became effective January 10, 2020, immediately following the expiration of his prior employment agreement. The employment agreement provides for an annual salary of $300,000 and term ending January 10, 2023, subject to certain automatic renewal provisions. On September 16, 2019, the Company entered into a The Company entered into an employment agreement with Mr. Daniel Stokely, Chief Financial Officer, on July 9, 2019, which provided for an annual salary of $285,000 and a term beginning July 31, 2019 and lasting for three years, subject to certain automatic renewal provisions. Amounts noted above do not assume the continuation of employment beyond the contractual terms of each employee’s existing employment agreements. Commercial Insurance Premium Financing Agreement In June 2021, the Company entered into an insurance premium financing agreement for $0.9 million, with a term of nine months and an annual interest rate of 3.57%. Under the terms and provisions of the agreement, the Company will be required to make principal and interest payments totaling $82,000 per month over the remaining term of the agreement. The outstanding obligation as of June 30, 2021 was $734,000, which will be paid in full by March 2022. In addition, as of June 30, 2021, the Company had a remaining balance of $74,000 related to annual insurance premiums payable to the Company’s insurance broker, which will be paid in full by March 2022. ​ Statistical Analysis and Programming Consulting Services In May 2019, the Company entered into a statistical analysis and programming consulting services agreement for $578,000. As of June 30, 2021, the Company had incurred cumulative costs totaling $252,000 against the contract and, as such, had an outstanding obligation of $326,000, which is expected to be settled by fiscal 2022. Facility Lease In December 2013, the Company entered into a 125-month “Leases (Topic 842)” determining the present value of the lease payments. Lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. The lease liability is classified both as current in part and long-term in part on the balance sheet based on the projected settlement of the liability. The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability disclosed on the balance sheet as of June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Facility Lease Payments Remainder of 2022 2023 2024 2025 Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining Facility Lease Payments ​ $ 1,173,000 ​ $ 174,000 ​ $ 355,000 ​ $ 364,000 ​ $ 280,000 ​ $ — ​ $ — Less: Discount Adjustment ​ (102,000) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total lease liability ​ $ 1,071,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liability-current portion ​ $ 298,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term lease liability ​ $ 773,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The following table provides a reconciliation of the Company’s remaining ROU asset for its facility lease presented in the balance sheet as of June 30, 2021: ​ ​ ​ ​ ​ ​ ROU Asset ​ ​ ​ Balance as of December 31, 2020 ​ $ 824,000 Amortization ​ ​ (96,000) Balance as of June 30, 2021 ​ $ 728,000 ​ The Company recorded lease expense in the respective periods is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease expense ​ $ 67,000 ​ $ 66,000 ​ $ 140,000 ​ $ 132,000 ​ ​

Warrants

Warrants	6 Months Ended
	Jun. 30, 2021
Warrants
Warrants	Note 8 – Warrants The Company has issued both equity (“placement agent”) and liability (“investor”) classified warrants in conjunction with previous equity raises. The Company had a total of 1.6 million equity-classified warrants and 2.2 million liability-classified warrants outstanding as of June 30, 2021. ​ The following table summarizes the Company’s warrant activity during the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ Number of ​ Average ​ Remaining ​ ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of December 31, 2020 ​ 4,130,724 ​ $ 0.66 ​ 2.05 Warrants exercised ​ (357,126) ​ $ 0.42 ​ — Outstanding as of June 30, 2021 3,773,598 ​ $ 0.68 1.49 ​ ​ The following table summarizes the Company’s outstanding warrants between placement agent and investor warrant classifications: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ Number of ​ Average ​ Remaining ​ ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ Investor warrants at $0.76 ​ 2,026,915 ​ ​ ​ ​ 0.92 Placement agent warrants at $0.76 ​ 422,233 ​ ​ ​ ​ 0.92 Placement agent warrants at $0.94 ​ 150,000 ​ ​ ​ ​ 0.16 Investor warrants at $0.40 ​ 153,400 ​ ​ ​ ​ 2.12 Placement agent warrants at $0.50 ​ 1,021,050 ​ ​ ​ ​ 2.97 Outstanding as of June 30, 2021 3,773,598 ​ $ 0.68 1.49 ​ During the six months ended June 30, 2021, the Company issued 284,100 shares of its common stock as a result of the exercise of investor warrants with an exercise price of $0.40. The Company received proceeds of $114,000 during the period related to these investor warrant exercises. In addition, former placement agents elected to exercise 73,026 of their warrants utilizing the net exercise option, where the total number of shares of common stock issued was reduced to cover the exercise price and, as such, the Company issued 51,763 shares of common stock. The Company did not receive any cash related to the exercise of placement agent warrants. The total value for the warrant derivative liability as of June 30, 2021 is approximately $2.3 million (see Note 9

Fair Value Considerations

Fair Value Considerations	6 Months Ended
	Jun. 30, 2021
Fair Value Considerations [Abstract]
Fair Value Considerations	Note 9 - Fair Value Considerations Authoritative guidance defines fair value as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs reflect inputs that market participants would use in pricing the asset or liability based on market data obtained from sources not affiliated with the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to the Company for identical assets or liabilities; Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. ​ The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. Warrants are recorded at estimated fair value utilizing the Black-Scholes warrant pricing model. The Company’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company’s policy is to recognize transfers in and/or out of the fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques in all periods presented. The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements Using ​ Level 1 Level 2 Level 3 Total June 30, 2021 ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 2,340,000 ​ $ 2,340,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 2,607,000 ​ $ 2,607,000 ​ The warrant derivative liability for both periods presented was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments. The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: ​ ​ ​ ​ ​ Derivative Instruments ​ ​ ​ ​ Balance as of December 31, 2020 ​ $ 2,607,000 Warrant exercises ​ (347,000) Change in fair value ​ 80,000 Balance as of June 30, 2021 ​ $ 2,340,000 ​

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Common stock	Note 10 - Common Stock Authorized Shares The Company had 300.0 million authorized shares of common stock as of June 30, 2021 and December 31, 2020. The following table summarizes the Company’s remaining authorized shares available for future issuance: ​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ Authorized shares ​ 300,000,000 ​ ​ ​ Common stock outstanding ​ 200,070,419 Options outstanding ​ 5,686,989 Warrants outstanding ​ 3,773,598 Reserved for issuance under 2019 Stock and Incentive Plan ​ 7,918,755 ​ ​ ​ Available shares ​ 82,550,239 ​ ATM Equity Offering Program In February 2020, the Company entered into a Sales Agreement with two agents to implement an ATM equity offering program under which the Company, from time to time and at its sole discretion, may offer and sell shares of its common stock having an aggregate offering price up to $50.0 million to the public through the agents until (i) each agent declines to accept the terms for any reason, (ii) the entire amount of shares has been sold, or (iii) the Company suspends or terminates the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the agents shall use their commercially reasonable efforts to sell shares from time to time, based upon the Company’s instructions as documented on a purchase notification form. If an agent declines to accept the purchase notification form, the agent must promptly notify the Company and the other agent then has the ability to accept or decline the purchase notification form. The Company has no obligation to sell any shares and may, at any time and in its sole discretion, suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The Sales Agreement includes customary indemnification rights in favor of the agents and provides that the agents will be entitled to an aggregate fixed commission of 4.0% of the gross proceeds (2.0% to each agent) to the Company from any shares sold pursuant to the Sales Agreement. The following table summarizes the Company’s sales and related issuance costs incurred under the Sales Agreement during the three months ended March 31, 2021 and June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Three months ended ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total shares of common stock sold ​ ​ 1,848,437 ​ ​ 4,066,773 ​ ​ 5,915,210 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross proceeds ​ $ 2,705,000 ​ $ 7,267,000 ​ $ 9,972,000 Commissions earned by placement agents ​ ​ (109,000) ​ ​ (291,000) ​ ​ (400,000) Issuance fees ​ ​ (17,000) ​ ​ (30,000) ​ ​ (47,000) Net proceeds ​ $ 2,579,000 ​ $ 6,946,000 ​ $ 9,525,000 ​ Common Stock Issued for Services The Company issued 54,052 and 136,236 shares of common stock under the Ampio Pharmaceuticals, Inc. 2019 Stock and Incentive Plan (the “2019 Plan”), each valued at $80,000, as partial compensation for the services of non-employee directors, during the six months ended June 30, 2021 and 2020, respectively.

Equity

Equity	6 Months Ended
	Jun. 30, 2021
Equity
Equity	Note 11 - Equity Options In December 2019, the Company’s Board of Directors and stockholders approved the adoption of the 2019 Plan, under which shares were reserved for future issuance of equity related awards classified as option awards/grants, restricted stock awards and other equity related awards. The 2019 Plan permits grants of equity awards to employees, directors and consultants. The stockholders approved a total of 10.0 million shares to be reserved for issuance under the 2019 Plan. The Company’s previous 2010 Stock and Incentive Plan (the “2010 Plan”) was cancelled concurrently with the adoption of the 2019 Plan. The following table summarizes the activity of the 2019 Plan and the shares available for future equity awards as of June 30, 2021: ​ ​ ​ ​ ​ 2019 Plan ​ ​ ​ ​ Total shares reserved for equity awards ​ ​ 10,000,000 Options granted during previous fiscal years ​ (2,067,471) Options granted during fiscal 2021 ​ ​ (36,000) Forfeited, expired and/or cancelled equity awards ​ 22,226 Remaining shares available for future equity awards ​ ​ 7,918,755 ​ The following table summarizes the Company’s stock option activity during the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ ​ ​ Number of ​ Average ​ Remaining ​ ​ Aggregate ​ ​ Options ​ Exercise Price ​ Contractual Life ​ ​ Intrinsic Value Outstanding as of December 31, 2020 6,099,651 ​ $ 1.04 7.36 $ — Granted 36,000 ​ $ 1.76 ​ ​ ​ Exercised (443,662) ​ $ 0.55 ​ ​ ​ Forfeited, expired and/or cancelled (5,000) ​ $ 1.75 ​ ​ ​ Outstanding as of June 30, 2021 5,686,989 ​ $ 1.08 6.92 $ 4,661,000 Exercisable as of June 30, 2021 5,413,989 ​ $ 1.09 6.80 $ 4,471,000 ​ Of the 443,662 stock options that were exercised during the six months ended June 30, 2021, 8,000 stock options were cash exercised whereby the Company received proceeds to cover the option holder’s exercise price and tax obligations totaling $6,000. In addition, 302,734 stock options were exercised as cashless exercises whereby the Company received proceeds to cover the option holders’ exercise price totaling $154,000. The remaining 132,928 stock options were net exercised whereby the total number of shares of common stock issued was reduced to cover the option holders’ exercise price and tax obligations. The Company submitted the tax obligations totaling $40,000 on behalf of the option holders. The shares of common stock that are held back upon a net exercise of a stock option to settle the option holder’s obligation associated with the exercise price and tax obligations are added back to the reserve for shares available for future equity awards under the 2019 Plan. The following table summarizes the outstanding options that were issued in accordance with the 2010 Plan and the 2019 Plan: ​ ​ ​ ​ Outstanding Options by Plan ​ June 30, 2021 2010 Plan ​ ​ 3,640,018 2019 Plan ​ ​ 2,046,971 Outstanding as of June 30, 2021 ​ ​ 5,686,989 ​ Stock options outstanding as of June 30, 2021 are summarized in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Weighted Average ​ ​ Options ​ Average ​ Remaining Range of Exercise Prices ​ Outstanding ​ Exercise Price ​ Contractual Lives Up to $0.50 494,500 ​ $ 0.44 8.17 $0.51 - $1.00 4,152,345 ​ $ 0.71 7.14 $1.01 - $1.50 ​ 187,000 ​ $ 1.39 ​ 9.38 $1.51 and above 853,144 ​ $ 3.23 4.59 Total 5,686,989 ​ $ 1.08 6.92 ​ The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company computed the fair value of options granted/modified during the period ended June 30, 2021, using the following assumptions: ​ ​ ​ ​ ​ Expected volatility 127.17 % Risk free interest rate 0.78 % Expected term (years) 5.00 ​ Stock-based compensation expense related to the fair value of stock options is included in the statements of operations as research and development expenses or general and administrative expenses as set forth in the table below. The following table summarizes stock-based compensation expense (stock options and common stock issued for services) for the three and six months ended June 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Research and development expenses ​ ​ ​ ​ Stock-based compensation ​ $ — ​ $ 11,000 ​ $ 46,000 ​ $ 71,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ General and administrative expenses ​ ​ ​ ​ ​ Issuance of common stock for services ​ — ​ — ​ 80,000 ​ 80,000 Stock-based compensation ​ 67,000 ​ 53,000 ​ 187,000 ​ 206,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total stock-based compensation ​ $ 67,000 ​ $ 64,000 ​ $ 313,000 ​ $ 357,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrecognized expense as of June 30, 2021 ​ $ 98,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining years to vest ​ 1.12 ​ ​ ​ ​ ​ ​

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share
Earnings Per Share	Note 12 - Earnings Per Share Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is based on the treasury stock method and computed by dividing net loss available to common stockholders by the diluted weighted-average shares of common stock outstanding during each period. The Company’s potentially dilutive shares include stock options and warrants for the shares of common stock. The potentially dilutive shares are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when the effect is dilutive. The investor warrants are treated as equity in the calculation of diluted earnings per share in both the computation of the numerator and denominator, if dilutive. The following table sets forth the calculations of basic and diluted earnings per share for the three and six months ended June 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Net loss ​ $ (3,556,000) ​ $ (2,731,000) ​ $ (7,222,000) ​ $ (7,910,000) Less: decrease in fair value of investor warrants ​ ​ (116,000) ​ ​ — ​ ​ (267,000) ​ ​ (156,000) Loss available to common stockholders ​ $ (3,672,000) ​ $ (2,731,000) ​ $ (7,489,000) ​ $ (8,066,000) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 196,179,371 ​ ​ 166,392,893 ​ ​ 195,785,398 ​ ​ 162,723,309 Add: dilutive effect of equity instruments ​ ​ 5,268,667 ​ ​ — ​ ​ 5,199,951 ​ ​ 1,182,948 Diluted weighted-average shares outstanding ​ ​ 201,448,038 ​ ​ 166,392,893 ​ ​ 200,985,349 ​ ​ 163,906,257 Earnings per share – basic ​ $ (0.02) ​ $ (0.02) ​ $ (0.04) ​ $ (0.05) Earnings per share – diluted ​ $ (0.02) ​ $ (0.02) ​ $ (0.04) ​ $ (0.05) ​ ​ The potentially dilutive shares of common stock that have been excluded from the calculation of net loss per share because of their anti-dilutive effect are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Outstanding stock options 1,437,657 ​ 6,866,524 ​ 1,466,319 ​ 5,917,367 Warrants to purchase shares of common stock 2,754,263 ​ 5,374,832 ​ 2,794,317 ​ 5,141,041 Total potentially dilutive shares of common stock 4,191,920 ​ 12,241,356 ​ 4,260,636 ​ 11,058,408 ​

Litigation

Litigation	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Litigation	Note 13 – Litigation From time to time, the Company may be a party to litigation arising in the ordinary course of business. As of June 30, 2021, the Company is not a party to any ongoing lawsuits. ​

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events
Subsequent Events	Note 14 – Subsequent Events ​ In July 2021, the Company received additional gross proceeds of $0.5 million from the sale of 330,875 shares of common stock in an ATM offering pursuant to the Sales Agreement, which was offset by offering related costs of $22,000. ​

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
The Company and Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation ​ The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions of the SEC on Quarterly Reports on Form 10-Q and Article 8 of Regulation S-X. Accordingly, such financial statements do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the financial position and of the results of operations and cash flows of the Company for the periods presented. ​ These financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2020 included in the Company’s 2020 Annual Report. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The information as of and for the three and six months ended June 30, 2021 is unaudited. The balance sheet at December 31, 2020 was derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.
Impact of Global Pandemic	Impact of Global Pandemic ​ In January 2020, the Secretary of Health and Human Services (“HHS”) declared a public health emergency and the World Health Organization (“WHO”) announced a global health emergency because of the novel Coronavirus Disease 2019 (“COVID-19”). In March 2020, the WHO declared the outbreak of COVID-19, a global pandemic. Since the declaration of the outbreak, COVID-19 has adversely impacted and continues to adversely impact the United States and global economies. In April 2020, and pursuant to the U.S. Food and Drug Administration (“FDA”), independent Safety Monitoring Committee (“SMC”), and Institutional Review Board guidance covering ongoing clinical trials in the presence of the COVID-19 pandemic, the Company and the clinical research organization (“CRO”) paused all ongoing conduct associated with the Phase III clinical trial (the “AP-013 study”) of Ampion for the treatment of Osteoarthritis of the Knee (“OAK”). In March 2021, the Company submitted a detailed proposal to the FDA in response to the FDA’s guidance regarding the status of the AP-013 study. In April 2021, the Company received a response to the proposal from the FDA, which provides guidance and flexibility on how to maintain the Special Protocol Assessment (“SPA”), while allowing the Company to evaluate and consider several paths for moving forward. In May 2021, the FDA issued updated statistical guidance for the industry. At this time, the Company is evaluating its options to analyze the clinical trial data from the AP-013 study. ​ In addition, since June 2020, the Company has commenced several clinical trials to determine the safety and efficacy for new applications of Ampion (i.e., inhaled and intravenous) related to COVID-19 infection. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the Company’s business operations could be significantly impacted and, in addition, the business operations of third parties on which the Company relies, including organizations that conduct clinical trials and key suppliers which provide the raw materials for manufacturing Ampion for the ongoing clinical trials could also be impacted. The full extent of the potential adverse impact on the Company’s business operations and related current and future product development, including, but not limited to, clinical trials, financing activities and the overall impact on the United States and the global economy will depend on future developments related to the pandemic, which cannot be predicted at this time.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and fully liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. During the three and six months ended June 30, 2021, and as consistent with prior reporting periods, the Company maintained balances in excess of federally insured limits.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions primarily include the Company’s projected liquidity and resulting going concern position, clinical trial accrual and the projected useful lives and potential impairment of fixed assets. The Company develops these estimates using its judgment based upon the facts and circumstances known at the time.
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company has not adopted any recent accounting pronouncements during the six months ended June 30, 2021. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “ Debt (Subtopic 470-20); Debt with Conversion and Other Options and Derivatives and Hedging (Subtopic 815-40) Contracts in Entity’s Own Equity This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	6 Months Ended
	Jun. 30, 2021
Prepaid Expenses and Other
Schedule Of Prepaid Expenses and other balances	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ ​ ​ ​ ​ Deposits ​ $ 1,236,000 ​ $ 266,000 Unamortized commercial insurance premiums ​ ​ 981,000 ​ ​ 627,000 Annual maintenance service contracts ​ ​ 63,000 ​ ​ — Receivable ​ ​ 30,000 ​ ​ 185,000 Other ​ ​ 48,000 ​ ​ 69,000 Total prepaid expenses and other ​ $ 2,358,000 ​ $ 1,147,000

Fixed Assets (Tables)

Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Fixed Assets
Schedule of Fixed Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated ​ ​ ​ ​ ​ ​ Useful Lives ​ June 30, ​ December 31, ​ (in Years) 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements 10 ​ $ 1,950,000 ​ $ 2,250,000 Manufacturing facility/clean room 3 - 8 ​ ​ 834,000 ​ ​ 998,000 Lab equipment and office furniture 5 - 8 ​ 290,000 ​ 313,000 Fixed assets, net ​ ​ ​ $ 3,074,000 ​ $ 3,561,000
Schedule Of Depreciation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization expense ​ $ 274,000 ​ $ 296,000 ​ $ 568,000 ​ $ 591,000 ​

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Accounts Payable and Accrued Expenses
Schedule of accounts payable and accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ ​ ​ ​ ​ Accounts payable ​ $ 170,000 ​ $ 186,000 Clinical trials ​ ​ 1,525,000 ​ ​ 558,000 Commercial insurance premium financing ​ 808,000 ​ 386,000 Professional fees ​ 380,000 ​ 267,000 Other ​ ​ 54,000 ​ ​ 153,000 Accounts payable and accrued expenses ​ $ 2,937,000 ​ $ 1,550,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total 2021 2022 2023 2024 2025 Thereafter Key clinical research trial obligations ​ $ 3,896,000 ​ $ 2,768,000 ​ $ 1,128,000 ​ $ — ​ $ — ​ $ — ​ $ — Employment agreements ​ ​ 830,000 ​ ​ 351,000 ​ ​ 466,000 ​ ​ 13,000 ​ ​ — ​ ​ — ​ ​ — Commercial insurance premium financing agreement ​ ​ 808,000 ​ ​ 539,000 ​ ​ 269,000 ​ ​ — ​ ​ — ​ ​ — ​ ​ — Statistical analysis and programming consulting services ​ ​ 326,000 ​ ​ 163,000 ​ ​ 163,000 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ $ 5,860,000 ​ $ 3,821,000 ​ $ 2,026,000 ​ $ 13,000 ​ $ — ​ $ — ​ $ —
Summary of reconciliation of the Company's undiscounted payments for its facility lease and the carrying amount of the lease liability	The following table provides a reconciliation of the Company’s remaining undiscounted payments for its facility lease and the carrying amount of the lease liability disclosed on the balance sheet as of June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Facility Lease Payments Remainder of 2022 2023 2024 2025 Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Remaining Facility Lease Payments ​ $ 1,173,000 ​ $ 174,000 ​ $ 355,000 ​ $ 364,000 ​ $ 280,000 ​ $ — ​ $ — Less: Discount Adjustment ​ (102,000) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total lease liability ​ $ 1,071,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liability-current portion ​ $ 298,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term lease liability ​ $ 773,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Lease Expense	The following table provides a reconciliation of the Company’s remaining ROU asset for its facility lease presented in the balance sheet as of June 30, 2021: ​ ​ ​ ​ ​ ​ ROU Asset ​ ​ ​ Balance as of December 31, 2020 ​ $ 824,000 Amortization ​ ​ (96,000) Balance as of June 30, 2021 ​ $ 728,000 ​ The Company recorded lease expense in the respective periods is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2021 2020 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease expense ​ $ 67,000 ​ $ 66,000 ​ $ 140,000 ​ $ 132,000 ​

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Warrants
Summary of Company's warrant activity	The following table summarizes the Company’s warrant activity during the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ Number of ​ Average ​ Remaining ​ ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ Outstanding as of December 31, 2020 ​ 4,130,724 ​ $ 0.66 ​ 2.05 Warrants exercised ​ (357,126) ​ $ 0.42 ​ — Outstanding as of June 30, 2021 3,773,598 ​ $ 0.68 1.49
Schedule of stockholders equity note warrants or rights classified as equity and liability	The following table summarizes the Company’s outstanding warrants between placement agent and investor warrant classifications: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ Number of ​ Average ​ Remaining ​ ​ Warrants ​ Exercise Price ​ Contractual Life ​ ​ ​ ​ ​ ​ ​ ​ Investor warrants at $0.76 ​ 2,026,915 ​ ​ ​ ​ 0.92 Placement agent warrants at $0.76 ​ 422,233 ​ ​ ​ ​ 0.92 Placement agent warrants at $0.94 ​ 150,000 ​ ​ ​ ​ 0.16 Investor warrants at $0.40 ​ 153,400 ​ ​ ​ ​ 2.12 Placement agent warrants at $0.50 ​ 1,021,050 ​ ​ ​ ​ 2.97 Outstanding as of June 30, 2021 3,773,598 ​ $ 0.68 1.49

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Considerations [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2021 and December 31, 2020, by level within the fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements Using ​ Level 1 Level 2 Level 3 Total June 30, 2021 ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 2,340,000 ​ $ 2,340,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Warrant derivative liability ​ $ — ​ $ — ​ $ 2,607,000 ​ $ 2,607,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: ​ ​ ​ ​ ​ Derivative Instruments ​ ​ ​ ​ Balance as of December 31, 2020 ​ $ 2,607,000 Warrant exercises ​ (347,000) Change in fair value ​ 80,000 Balance as of June 30, 2021 ​ $ 2,340,000

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Schedule of remaining authorized Shares	​ ​ ​ ​ ​ June 30, 2021 ​ ​ ​ Authorized shares ​ 300,000,000 ​ ​ ​ Common stock outstanding ​ 200,070,419 Options outstanding ​ 5,686,989 Warrants outstanding ​ 3,773,598 Reserved for issuance under 2019 Stock and Incentive Plan ​ 7,918,755 ​ ​ ​ Available shares ​ 82,550,239
Schedule of sale of stock under sales agreement	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended ​ Three months ended ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total shares of common stock sold ​ ​ 1,848,437 ​ ​ 4,066,773 ​ ​ 5,915,210 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross proceeds ​ $ 2,705,000 ​ $ 7,267,000 ​ $ 9,972,000 Commissions earned by placement agents ​ ​ (109,000) ​ ​ (291,000) ​ ​ (400,000) Issuance fees ​ ​ (17,000) ​ ​ (30,000) ​ ​ (47,000) Net proceeds ​ $ 2,579,000 ​ $ 6,946,000 ​ $ 9,525,000

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Summary of Stock Options Outstanding and Exercisable	Stock options outstanding as of June 30, 2021 are summarized in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Weighted Average ​ ​ Options ​ Average ​ Remaining Range of Exercise Prices ​ Outstanding ​ Exercise Price ​ Contractual Lives Up to $0.50 494,500 ​ $ 0.44 8.17 $0.51 - $1.00 4,152,345 ​ $ 0.71 7.14 $1.01 - $1.50 ​ 187,000 ​ $ 1.39 ​ 9.38 $1.51 and above 853,144 ​ $ 3.23 4.59 Total 5,686,989 ​ $ 1.08 6.92
Assumptions Used in Computing Fair Value of All Options Granted	​ ​ ​ ​ ​ Expected volatility 127.17 % Risk free interest rate 0.78 % Expected term (years) 5.00
Summary of Stock-Based Compensation Expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Research and development expenses ​ ​ ​ ​ Stock-based compensation ​ $ — ​ $ 11,000 ​ $ 46,000 ​ $ 71,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ General and administrative expenses ​ ​ ​ ​ ​ Issuance of common stock for services ​ — ​ — ​ 80,000 ​ 80,000 Stock-based compensation ​ 67,000 ​ 53,000 ​ 187,000 ​ 206,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total stock-based compensation ​ $ 67,000 ​ $ 64,000 ​ $ 313,000 ​ $ 357,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrecognized expense as of June 30, 2021 ​ $ 98,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining years to vest ​ 1.12 ​ ​ ​ ​ ​
Employee Stock Option
Stock Option Activity	The following table summarizes the Company’s stock option activity during the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Weighted Average ​ ​ ​ ​ Number of ​ Average ​ Remaining ​ ​ Aggregate ​ ​ Options ​ Exercise Price ​ Contractual Life ​ ​ Intrinsic Value Outstanding as of December 31, 2020 6,099,651 ​ $ 1.04 7.36 $ — Granted 36,000 ​ $ 1.76 ​ ​ ​ Exercised (443,662) ​ $ 0.55 ​ ​ ​ Forfeited, expired and/or cancelled (5,000) ​ $ 1.75 ​ ​ ​ Outstanding as of June 30, 2021 5,686,989 ​ $ 1.08 6.92 $ 4,661,000 Exercisable as of June 30, 2021 5,413,989 ​ $ 1.09 6.80 $ 4,471,000 The following table summarizes the outstanding options that were issued in accordance with the 2010 Plan and the 2019 Plan: ​ ​ ​ ​ Outstanding Options by Plan ​ June 30, 2021 2010 Plan ​ ​ 3,640,018 2019 Plan ​ ​ 2,046,971 Outstanding as of June 30, 2021 ​ ​ 5,686,989
2019 Stock plan
Stock Option Activity	The following table summarizes the activity of the 2019 Plan and the shares available for future equity awards as of June 30, 2021: ​ ​ ​ ​ ​ 2019 Plan ​ ​ ​ ​ Total shares reserved for equity awards ​ ​ 10,000,000 Options granted during previous fiscal years ​ (2,067,471) Options granted during fiscal 2021 ​ ​ (36,000) Forfeited, expired and/or cancelled equity awards ​ 22,226 Remaining shares available for future equity awards ​ ​ 7,918,755

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share
Schedule for the calculations of basic and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Net loss ​ $ (3,556,000) ​ $ (2,731,000) ​ $ (7,222,000) ​ $ (7,910,000) Less: decrease in fair value of investor warrants ​ ​ (116,000) ​ ​ — ​ ​ (267,000) ​ ​ (156,000) Loss available to common stockholders ​ $ (3,672,000) ​ $ (2,731,000) ​ $ (7,489,000) ​ $ (8,066,000) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted-average common shares outstanding ​ ​ 196,179,371 ​ ​ 166,392,893 ​ ​ 195,785,398 ​ ​ 162,723,309 Add: dilutive effect of equity instruments ​ ​ 5,268,667 ​ ​ — ​ ​ 5,199,951 ​ ​ 1,182,948 Diluted weighted-average shares outstanding ​ ​ 201,448,038 ​ ​ 166,392,893 ​ ​ 200,985,349 ​ ​ 163,906,257 Earnings per share – basic ​ $ (0.02) ​ $ (0.02) ​ $ (0.04) ​ $ (0.05) Earnings per share – diluted ​ $ (0.02) ​ $ (0.02) ​ $ (0.04) ​ $ (0.05)
Potentially dilutive securities, excluded	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Outstanding stock options 1,437,657 ​ 6,866,524 ​ 1,466,319 ​ 5,917,367 Warrants to purchase shares of common stock 2,754,263 ​ 5,374,832 ​ 2,794,317 ​ 5,141,041 Total potentially dilutive shares of common stock 4,191,920 ​ 12,241,356 ​ 4,260,636 ​ 11,058,408

Going Concern (Detail)

Going Concern (Detail)	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 29, 2020item	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Cash and cash equivalents		$ 20,549,000		$ 20,549,000			$ 17,346,000
Net loss		(3,556,000)	$ (2,731,000)	(7,222,000)	$ (7,910,000)
Working capital		6,500,000		6,500,000
Operating expenses		3,673,000	2,600,000	7,491,000	8,622,000
Derivative gain (loss)		116,000	(675,000)	267,000	156,000
Accumulated deficit		(207,750,000)		(207,750,000)			(200,527,000)
Stockholders' equity		$ 20,361,000	$ 6,343,000	20,361,000	$ 6,343,000	$ 16,777,000	$ 17,512,000	$ 1,993,000	$ 6,443,000
ATM equity offering program
Gross proceeds				10,000,000
Offering related costs				$ 400,000
Sale Agreement (ATM)
Number of agents | item	2

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Other
Deposits	$ 1,236,000	$ 266,000
Unamortized commercial insurance premiums	981,000	627,000
Annual maintenance service contracts	63,000
Receivable	30,000	185,000
Other	48,000	69,000
Total prepaid expenses and other	$ 2,358,000	$ 1,147,000

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Fixed assets, net	$ 3,074,000	$ 3,561,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years	10 years
Fixed assets, gross	$ 1,950,000	2,250,000
Manufacturing facility/ clean room
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 834,000	998,000
Manufacturing facility/ clean room | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years	3 years
Manufacturing facility/ clean room | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years	8 years
Lab equipment and office furniture
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 290,000	$ 313,000
Lab equipment and office furniture | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years	5 years
Lab equipment and office furniture | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Lives in Years	8 years

Fixed Assets - Depreciation and

Fixed Assets - Depreciation and Amortization Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fixed Assets
Depreciation and amortization expense	$ 274,000	$ 296,000	$ 568,000	$ 591,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accounts Payable and Accrued Expenses
Accounts payable	$ 170,000	$ 186,000
Clinical trials	1,525,000	558,000
Commercial insurance premium financing	808,000	386,000
Professional fees	380,000	267,000
Other	54,000	153,000
Accounts payable and accrued expenses	$ 2,937,000	$ 1,550,000

Paycheck Protection Program - A

Paycheck Protection Program - Additional Information (Detail) - PPP	1 Months Ended
	Apr. 30, 2020USD ($)
Debt Instrument [Line Items]
PPP loan proceeds	$ 544,000
Interest rate (as a percentage)	1.00%
Term of agreement (in years)	6 months

Commitments and Contingencies -

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Jun. 30, 2021USD ($)
Commitment And Contingencies [Line Items]
2021	$ 3,821,000
2022	2,026,000
2023	13,000
2024	0
2025	0
Thereafter	0
Total	5,860,000
Key Clinical Research Trial Obligations
Commitment And Contingencies [Line Items]
2021	2,768,000
2022	1,128,000
2023	0
2024	0
2025	0
Thereafter	0
Total	3,896,000
Employment Agreements
Commitment And Contingencies [Line Items]
2021	351,000
2022	466,000
2023	13,000
2024	0
2025	0
Thereafter	0
Total	830,000
Commercial Insurance Premium Financing Agreement
Commitment And Contingencies [Line Items]
2021	539,000
2022	269,000
2023	0
2024	0
2025	0
Thereafter	0
Total	808,000
Statistical analysis and programming consulting services
Commitment And Contingencies [Line Items]
2021	163,000
2022	163,000
2023	0
2024	0
2025	0
Thereafter	0
Total	$ 326,000

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended
	Jun. 30, 2021	Apr. 30, 2020	Dec. 31, 2013	Mar. 31, 2021	Dec. 31, 2020	May 31, 2019
Commitments and Contingencies [Line Items]
Contractual obligation	$ 5,860,000
Facility Lease Incremental Borrowing Rate	5.75%
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period			125 months
Lease initial base rent per month			$ 23,000
Rent expense			$ 3,300,000
Key Clinical Research Trial Obligations
Commitments and Contingencies [Line Items]
Contractual obligation	$ 3,896,000
New CRO
Commitments and Contingencies [Line Items]
Contract amount					$ 1,400,000
Contractual deposit Commitment	315,000
Contractual obligation	382,000
Intravenous treatment for COVID 19 patients
Commitments and Contingencies [Line Items]
Contract amount					1,800,000
Contractual deposit Commitment					$ 345,000
Contractual obligation	1,200,000
Regional Hospital Group, AP-018 Study
Commitments and Contingencies [Line Items]
Contract amount				$ 318,000
Contractual deposit Commitment				$ 105,000
Contractual obligation	130,000
Regional Hospital Group, AP-019 Study [Member]
Commitments and Contingencies [Line Items]
Contract amount	2,500,000
Contractual deposit Commitment	300,000
Contractual obligation	2,200,000
Statistical analysis and programming consulting services
Commitments and Contingencies [Line Items]
Contract amount						$ 578,000
Contractual obligation	326,000
Amount Incurred Against Contract Obligation	252,000
PPP
Commitments and Contingencies [Line Items]
Term of agreement (in years)		6 months
Interest rate (as a percentage)		1.00%
Commercial Insurance Premium Financing Agreement
Commitments and Contingencies [Line Items]
Financing agreement amount	$ 900,000
Term of agreement (in years)	9 months
Interest rate (as a percentage)	3.57%
Principal and interest payments per month	$ 82,000
Contractual obligation	734,000
Insurance premiums	$ 74,000

Commitments and Contingencies_3

Commitments and Contingencies - Employment Agreements (Detail) - USD ($)	Dec. 14, 2019	Sep. 16, 2019	Jul. 09, 2019
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Term of employment agreement (in years)	3 years
Annual Salary	$ 300,000
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Term of employment agreement (in years)		2 years
Annual Salary		$ 280,000
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Term of employment agreement (in years)			3 years
Annual Salary			$ 285,000

Commitments and Contingencies_4

Commitments and Contingencies - Summary of Reconciliation of Company's Undiscounted Payments for Facility Lease and Carrying Amount of Lease Liability (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remainder of 2021	$ 174,000
2022	355,000
2023	364,000
2024	280,000
Remaining Facility Lease Payments	1,173,000
Less: Discount Adjustment	(102,000)
Total lease liability	1,071,000
Lease liability - current portion	298,000	$ 284,000
Long-term lease liability	$ 773,000	$ 925,000

Commitments and Contingencies_5

Commitments and Contingencies - Lease Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Balance as of December 31, 2020			$ 824,000
Amortization			(96,000)
Balance as of June 30, 2021	$ 728,000		728,000
Lease expense	$ 67,000	$ 66,000	$ 140,000	$ 132,000

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Number of Warrants Outstanding
Class of Warrant or Right, Outstanding	3,773,598	4,130,724
Number of Warrants Outstanding, Beginning Balance	4,130,724
Number of Warrants, Warrants exercised	(357,126)
Number of Warrants Outstanding, Ending Balance	3,773,598	4,130,724
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.66
Weighted Average Exercise Price, Warrants exercised	0.42
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.68	$ 0.66
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	1 year 5 months 26 days	2 years 18 days
Equity based-warrants
Number of Warrants Outstanding
Class of Warrant or Right, Outstanding	1,600,000
Number of Warrants Outstanding, Ending Balance	1,600,000
Liability warrants
Number of Warrants Outstanding
Class of Warrant or Right, Outstanding	2,200,000
Number of Warrants Outstanding, Ending Balance	2,200,000

Warrants - Warrants Activity Cl

Warrants - Warrants Activity Classified as Equity and Liability (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	3,773,598	4,130,724
Exercise price	$ 0.68	$ 0.66
Weighted Average Remaining Contractual Life, Warrants Outstanding	1 year 5 months 26 days	2 years 18 days
Investor warrants at $0.76
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	2,026,915
Exercise price	$ 0.76
Weighted Average Remaining Contractual Life, Warrants Outstanding	11 months 1 day
Placement agent warrants at $0.76
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	422,233
Exercise price	$ 0.76
Weighted Average Remaining Contractual Life, Warrants Outstanding	11 months 1 day
Placement agent warrants at $0.94
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	150,000
Exercise price	$ 0.94
Weighted Average Remaining Contractual Life, Warrants Outstanding	1 month 28 days
Investor warrants at $0.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	153,400
Exercise price	$ 0.40
Weighted Average Remaining Contractual Life, Warrants Outstanding	2 years 1 month 13 days
Placement agent warrants at $0.50
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants Outstanding, Ending Balance	1,021,050
Exercise price	$ 0.50
Weighted Average Remaining Contractual Life, Warrants Outstanding	2 years 11 months 19 days

Warrants - Narrative (Detail)

Warrants - Narrative (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Exercise price	$ 0.68	$ 0.66
Warrant derivative liability	$ 2,340,000	$ 2,607,000
Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Common shares issued for warrant exercised	284,100
Exercise price	$ 0.40
Proceeds from warrant exercises	$ 114,000
Number Of Warrants Exercised By Placement Agents	73,026
Stock Issued On Exercise Of Warrants By Placement Agents	51,763

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Detail) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
LIABILITIES
Warrant derivative liability	$ 2,340,000	$ 2,607,000
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 2,340,000	$ 2,607,000

Fair Value Considerations - Set

Fair Value Considerations - Sets Forth a Reconciliation of Changes (Detail)	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Balance as of December 31, 2020	$ 2,607,000
Warrants exercises	(347,000)
Change in fair value	80,000
Balance as of June 30, 2021	$ 2,340,000

Common Stock (Summarizes the Co

Common Stock (Summarizes the Company's remaining authorized shares available - (Detail) - shares	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Authorized shares	300,000,000	300,000,000
Common stock outstanding	200,070,419	193,378,996
Options Outstanding	5,686,989
Warrants Outstanding	3,773,598	4,130,724
Reserved for issuance under 2019 Stock and Incentive Plan	7,918,755
Available Shares	82,550,239

Common Stock (Sales Agreement)

Common Stock (Sales Agreement) (Detail) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 29, 2020USD ($)item	Jun. 30, 2021USD ($)shares	Mar. 31, 2021USD ($)shares	Jun. 30, 2021USD ($)shares
Class of Stock [Line Items]
Total shares of common stock sold | shares		4,066,773	1,848,437
Gross Proceeds		$ 7,267	$ 2,705
Commissions earned by placement agents		(291)	(109)
Issuance fees		(30)	(17)
Net Proceeds		$ 6,946	$ 2,579
Sale Agreement (ATM)
Class of Stock [Line Items]
Number of agents | item	2
Maximum aggregate offering price of equity securities	$ 50,000
Percentage of commission	4.00%
Sales Agreement
Class of Stock [Line Items]
Total shares of common stock sold | shares				5,915,210
Gross Proceeds				$ 9,972
Commissions earned by placement agents				(400)
Issuance fees				(47)
Net Proceeds				$ 9,525
Sales Agreement Agent [Member] | Sale Agreement (ATM)
Class of Stock [Line Items]
Percentage of commission	2.00%

Common Stock (Common Stock Issu

Common Stock (Common Stock Issued for Services) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Components of common Stock [Line Items]
Issuance of common stock for services	$ 80,000	$ 80,000
Common Stock Issued for Services [Member] | Non Employee Directors
Components of common Stock [Line Items]
Issuance of common stock for services (Shares)			54,052	136,236
Issuance of common stock for services			$ 80,000

Equity - Activity of Plan (Deta

Equity - Activity of Plan (Detail) - Employee Stock Option - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	(36,000)
Forfeited, expired and/or cancelled equity awards	5,000
2019 Stock plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for equity awards	10,000,000		10,000,000
Options granted	(36,000)	(2,067,471)
Forfeited, expired and/or cancelled equity awards	22,226
Remaining shares available for future equity awards	7,918,755

Equity - Stock Option Activity

Equity - Stock Option Activity (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Number of Options
Number of Options, Ending Balance	5,686,989
Employee Stock Option
Number of Options
Number of Options, Beginning Balance	6,099,651
Number of Options, Granted	36,000
Number of Options, Exercised	(443,662)
Number of Options, Forfeited, expired and/or cancelled	(5,000)
Number of Options, Ending Balance	5,686,989	6,099,651
Number of Options, Exercisable	5,413,989
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 1.04
Weighted Average Exercise Price, Granted | $ / shares	1.76
Weighted Average Exercise Price, Exercised | $ / shares	0.55
Weighted Average Exercise Price, Forfeited, expired and/or cancelled | $ / shares	1.75
Weighted Average Exercise Price, Ending Balance | $ / shares	1.08	$ 1.04
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.09
Weighted Average Remaining Contractual Life, Outstanding	6 years 11 months 1 day	7 years 4 months 9 days
Weighted Average Remaining Contractual Life, Exercisable	6 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding | $	$ 4,661,000
Aggregate Intrinsic Value, Exercisable | $	$ 4,471,000
Stock options exercised (Shares)	443,662
Cash exercises of stock options (Shares)	8,000
Proceeds from cash exercises | $	$ 6,000
Cashless exercises of stock options (Shares)	302,734
Proceeds from cashless exercises | $	$ 154,000
Stock options exercised, net (Shares)	132,928
Tax obligations on behalf of option holders | $	$ 40,000
2010 Stock Plan
Number of Options
Number of Options, Ending Balance	3,640,018
2019 Stock plan
Number of Options
Number of Options, Ending Balance	2,046,971
2019 Stock plan | Employee Stock Option
Number of Options
Number of Options, Granted	36,000	2,067,471
Number of Options, Forfeited, expired and/or cancelled	(22,226)
Number of Options, Available for grant	7,918,755

Equity - Summary of Stock Optio

Equity - Summary of Stock Options Outstanding and Exercisable (Detail) - Employee Stock Option	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	5,686,989
Weighted Average Exercise Price	$ 1.08
Weighted Average Remaining Contractual Lives	6 years 11 months 1 day
Up to $0.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	494,500
Weighted Average Exercise Price	$ 0.44
Weighted Average Remaining Contractual Lives	8 years 2 months 1 day
Range of Exercise Prices Upper	$ 0.50
$0.51 - $1.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	4,152,345
Weighted Average Exercise Price	$ 0.71
Weighted Average Remaining Contractual Lives	7 years 1 month 20 days
Range of Exercise Prices Lower	$ 0.51
Range of Exercise Prices Upper	$ 1
$1.01 - $1.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	187,000
Weighted Average Exercise Price	$ 1.39
Weighted Average Remaining Contractual Lives	9 years 4 months 17 days
Range of Exercise Prices Lower	$ 1.01
Range of Exercise Prices Upper	$ 1.50
$1.51 and above
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	853,144
Weighted Average Exercise Price	$ 3.23
Weighted Average Remaining Contractual Lives	4 years 7 months 2 days
Range of Exercise Prices Lower	$ 1.51

Equity - Assumptions Used in Co

Equity - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	6 Months Ended
	Jun. 30, 2021
Equity
Expected volatility	127.17%
Risk free interest rate	0.78%
Expected term (years)	5 years

Equity - Summary of Stock-Based

Equity - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 67,000	$ 64,000	$ 313,000	$ 357,000
Unrecognized expense as of December 31, 2020	$ 98,000
Weighted average remaining years to vest	1 year 1 month 13 days
Research and Development Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses		11,000	46,000	71,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 0	0	80,000	80,000
General and Administrative Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 67,000	$ 53,000	$ 187,000	$ 206,000

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share
Net loss	$ (3,556,000)	$ (2,731,000)	$ (7,222,000)	$ (7,910,000)
Less: decrease in fair value of investor warrants	(116,000)		(267,000)	(156,000)
Loss available to common stockholders	$ (3,672,000)	$ (2,731,000)	$ (7,489,000)	$ (8,066,000)
Basic weighted-average common shares outstanding	196,179,371	166,392,893	195,785,398	162,723,309
Add: dilutive effect of equity instruments	5,268,667		5,199,951	1,182,948
Diluted weighted-average shares outstanding	201,448,038	166,392,893	200,985,349	163,906,257
Earnings per share - basic	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.05)
Earnings per share - diluted	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.05)

Earnings Per Share - Anti-dilut

Earnings Per Share - Anti-dilutive (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	4,191,920	12,241,356	4,260,636	11,058,408
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	1,437,657	6,866,524	1,466,319	5,917,367
Warrant to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares of common stock	2,754,263	5,374,832	2,794,317	5,141,041

Subsequent Events - (Detail)

Subsequent Events - (Detail) - USD ($)	1 Months Ended	3 Months Ended				6 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Subsequent Event [Line Items]
Proceeds from sale of common stock in connection with "at-the-market" equity offering program						$ 9,972,000	$ 7,913,000
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program		$ 321,000	$ 126,000	$ 314,000	$ 246,000
Subsequent Event | Sale Agreement (ATM)
Subsequent Event [Line Items]
Proceeds from sale of common stock in connection with "at-the-market" equity offering program	$ 500,000
Issuance of common stock (Shares)	330,875
Offering costs related to the issuance of common stock in connection with the "at-the-market" equity offering program	$ 22,000